Discrepancies between the K-ras mutational status of primary colorectal cancers and corresponding liver metastases are found in codon 13

Genomics

Volumn 106, Issue 2, 2015, Pages 71-75

  Kawamata, Hiroshi ^a   Yamashita, Keishi ^a   Kojo, Ken ^a   Ushiku, Hideki ^a   Ooki, Akira ^a   Watanabe, Masahiko ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Codon 13; Colorectal cancer; K ras mutation; Liver metastasis; Micrometastasis

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; CODON; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CODON; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MALE; METASTASIS RESECTION; ONCOGENE K RAS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; COLORECTAL TUMOR; GENETICS; LIVER TUMOR; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; SECONDARY;

CODON; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84937813496     PISSN: 08887543     EISSN: 10898646     Source Type: Journal    
DOI: 10.1016/j.ygeno.2015.05.007     Document Type: Article

References (31)

1. Downward J. Targeting RAS, signalling pathways in cancer therapy. Nat. Rev. Cancer 2003, 3(1):11-22.
2. Onozato W., Yamashita K., Yamashita K., Kuba T., Katoh H., Nakamura T., Sato T., Ihara A., Okayasu I., Watanabe M. Genetic alterations of K-ras may reflect prognosis in stage III colon cancer patients below 60years of age. J. Surg. Oncol. 2011, 103(1):25-33.
3. Zhang C., Guo W., Wu J., Song B., Zhang C., Dai Q., Pan B., Ji Y., Guo J. Differential high-resolution melting analysis for the detection of K-ras codons 12 and 13 mutations in pancreatic cancer. Pancreas 2011, 40(8):1283-1288.
4. Sugio K., Ishida T., Yokoyama H., Inoue T., Sugimachi K., Sasazuki T. ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res. 1992, 52(10):2903-2906.
5. Vogelstein B., Kinzler K. Cancer genes and the pathways they control. Nat. Med. 2004, 10(8):789-799.
6. International Agency for Research on Cancer WHO GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence http://globocaniarcfr/Pages/fact_sheets_canceraspx.
7. Yamashita K., Watanabe M. Clinical significance of tumor markers and an emerging perspective on colorectal cancer. Cancer Sci. 2009, 100(2):195-199.
8. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., Simes R.J., Chalchal H., Shapiro J.D., Robitaille S., Price T.J., Shepherd L., Au H.J., Langer C.M.M., Zalcberg J.R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008, 359(17):1757-1765.
9. Conlin A., Smith G., Carey F.A., Wolf C.R., Steele R.J. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut 2005, 54(9):1283-1286.
10. Bazan V., Migliavacca M., Zanna I., Tubiolo C., Grassi N., Latteri M.A., La Farina M., Albanese I.D.G., Salerno S., Tomasino R.M., Labianca R., Gebbia N., Russo A. Specific codon 13K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12K-ras mutations are associated with mucinous histotype. Ann. Oncol. 2002, 13(9):1438-1446.
11. Pricolo V.E., Finkelstein S.D., Wu T.T., Keller G., Bakker A., Swalsky P.A., Bland K.I. Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon. Am. J. Surg. 1996, 171(1):41-46.
12. Andersen S.N., Løvig T., Breivik J., Lund E., Gaudernack G., Meling G.I., Rognum T.O. K-ras mutations and prognosis in large-bowel carcinomas. Scand. J. Gastroenterol. 1997, 32(1):62-69.
13. Ren J., Li G., Ge J., Li X., Zhao Y. Is K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis. Dis. Colon Rectum 2012, 55(8):913-923.
14. Oudejans J.J., Slebos R.J., Zoetmulder F.A., Mooi W.J., Rodenhuis S. Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int. J. Cancer 1991, 49(6):875-879.
15. Petrowsky H., Sturm I., Graubitz O., Kooby D.A., Staib-Sebler E., Gog C., Köhne C.H., Hillebrand T.D.P., Fong Y., Lorenz M. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. Eur. J. Surg. Oncol. 2001, 27(1):80-87.
16. Moroni M., Veronese S., Benvenuti S., Marrapese G., Sartore-Bianchi A., Di Nicolantonio F., Gambacorta M., Siena S., Bardelli A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005, 6(5):279-286.
17. Finkelstein S.D., Sayegh R., Christensen S., Swalsky P.A. Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer 1993, 71(12):3827-3838.
18. Losi L., Luppi G., Benhattar J. Assessment of K-ras, Smad4 and p53 gene alterations in colorectal metastases and their role in the metastatic process. Oncol. Rep. 2004, 12(6):1221-1225.
19. Schimanski C.C., Linnemann U., Galle P.R., Arbogast R., Berger M.R. Hepatic disseminated tumor cells in colorectal cancer UICC stage 4 patients: prognostic implications. Int. J. Oncol. 2003, 23(3):791-796.
20. Linnemann U., Schmanski C.C., Gebhardt C., Berger M.R. Prognostic value of disseminated colorectal tumor cells in the liver: results of follow-up examinations. Int. J. Colorectal Dis. 2004, 19(4):380-386.
21. Conzelmann M., Linnemann U., Berger M.R. K-ras codon 12 and 13 mutations are correlated with differential patterns of tumor cell dissemination in colorectal cancer patients. Int. J. Oncol. 2004, 24(6):1537-1544.
22. Shirasawa S., Furuse M., Yokoyama N., Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993, 260(5104):85-88.
23. Vartanian S., Bentley C., Brauer M.J., Li L., Shirasawa S., Sasazuki T., Kim J.S., Haverty P., Stawiski E., Modrusan Z., Waldman T., Stokoe D. Identification of mutant K-ras-dependent phenotypes using a panel of isogenic cell lines. J. Biol. Chem. 2013, 288(4):2403-2413.
24. Rak J., Mitsuhashi Y., Bayko L., Filmus J., Shirasawa S., Sasazuki T., Kerbel R.S. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 1995, 55(20):4575-4580.
25. Okada F., Rak J.W., Croix B.S., Lieubeau B., Kaya M., Roncari L., Shirasawa S., Sasazuki T., Kerbel R.S. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(7):3609-3614.
26. Allgayer H., Wang H., Shirasawa S., Sasazuki T., Boyd D. Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis. Br. J. Cancer 1999, 80(12):1884-1891.
27. Pollock C.B., Shirasawa S., Sasazuki T., Kolch W., Dhillon A.S. Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. Cancer Res. 2005, 65(4):1244-1250.
28. Ries S., Biederer C., Woods D., Shifman O., Shirasawa S., Sasazuki T., McMahon M., Oren M., McCormick F. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 2000, 103(2):321-330.
29. Saha S., Bardelli A., Buckhaults P., Velculescu V.E., Rago C., St Croix B., Romans K.E., Choti M.A., Lengauer C., Kinzler K.W., Vogelstein B. A phosphatase associated with metastasis of colorectal cancer. Science 2001, 294(5545):1343-1346.
30. Bardelli A., Saha S., Sager J.A., Romans K.E., Xin B., Markowitz S.D., Lengauer C., Velculescu V.E., Kinzler K.W., Vogelstein B. PRL-3 expression in metastatic cancers. Clin. Cancer Res. 2003, 9(15):5607-5615.
31. Hatate K., Yamashita K., Hirai K., Kumamoto H., Sato T., Ozawa H., Nakamura T., Onozato W., Kokuba Y., Ihara A., Watanabe M. Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9. Oncol. Rep. 2008, 20(4):737-743.